Contact Lens For Prolonged Delivery of Glaucoma Medication - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Contact Lens For Prolonged Delivery of Glaucoma Medication



The concept of using contact lens for ocular drug-delivery applications is now one step closer to reaching the clinic. Researchers at Massachusetts recently reported on the development of a drug-eluting contact lens designed to provide prolonged delivery of the glaucoma medication, latanoprost.

In vitro and in vivo studies showed an initial burst of drug release from the contact lens followed by sustained release of latanoprost for one month. Drug levels in the aqueous humor were comparable to those achieved with topical latanoprost solution (eye drops), which is currently first-line treatment for glaucoma. These findings, available online, will be published in the January issue of Biomaterials.

The contact lens was made with materials that are FDA-approved for use on the eye. Latanoprost-poly(lactic-co-glycolic acid) films were encapsulated in methafilcon by ultraviolet light polymerization. The drug-polymer film at the periphery controls drug release.

“The lens we have developed is capable of delivering large amounts of drug at substantially constant rates over weeks to months,” said Professor Daniel Kohane, director of the Laboratory for Biomaterials and Drug Delivery at Boston Children’s Hospital, in a press statement. 


According to Joseph Ciolino, MD, lead author of the paper, eye drops are an inefficient method of drug delivery with poor patient adherence. “A non-invasive method of sustained ocular drug delivery could help patients adhere to the therapy necessary to maintain vision in diseases like glaucoma, saving millions from preventable blindness,” Ciolino added.

The contact lens has a clear central aperture and can be made with no refractive power or with the ability to correct refractive error in nearsighted or farsighted eyes. The novel design can be used as a platform for other ocular drug-delivery applications.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here